AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
9min chapter
Eli Lilly, Morphic Deal, Delta Earnings
Bloomberg Intelligence
Eli Lilly's Acquisition Strategy and Industry Innovations
The chapter explores Eli Lilly's $3.2 billion acquisition of Morphic to enhance their immunology franchise by focusing on new technologies and early stage deals. It discusses the pharmaceutical industry's trend of acquiring therapeutics through M&A deals, highlighting Lilly's strategy of bolt-on acquisitions in various therapeutic areas over the past five years. The episode also touches on advancements in different disease fields like obesity, oncology, inflammation, and neurodegenerative diseases, as well as the challenges in developing preventative drugs for complex conditions such as Alzheimer's.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode